Could a morning shot fight cancer better?
NCT ID NCT07155317
Summary
This study is testing whether giving two immunotherapy drugs (ipilimumab and nivolumab) at specific times of day improves how well they work for advanced melanoma. Researchers want to see if receiving treatment in the morning, afternoon, or late afternoon leads to better survival and fewer side effects. The trial will enroll 99 adults with stage IV or inoperable melanoma who haven't had recent immunotherapy.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLINICAL STAGE IV CUTANEOUS MELANOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
Emory Saint Joseph's Hospital
NOT_YET_RECRUITINGAtlanta, Georgia, 30342, United States
Contact
Contact Email: •••••@•••••
-
Emory University Hospital/Winship Cancer Institute
RECRUITINGAtlanta, Georgia, 30322, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.